Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among aging people globally. Around one in seven Australians over the age of 50 have some signs of AMD.

The disease results in blurred and distorted vision, and often loss of function at the center of the eye’s visual field.

The best current treatment involves a series of injections to slow the progression of the disease, but this process can be expensive and difficult with potentially negative long-term effects.